Detail akcie Supernus online

Business Summary: Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Supernus Pharmaceuticals Inc revenues increased 8% to $312M. Net income increased 24% to $20M. Revenues reflect Net product sales-Qelbree segment increase of 84% to $104.5M, Net product sales- Oxtellar XR segment increase of 7% to $56.5M. Net income benefited from Selling/General/Admin. Expense decrease of 16% to $114.8M (expense).